BJA Advance Access originally published online on February 25, 2005
British Journal of Anaesthesia 2005 94(5):586-591; doi:10.1093/bja/aei102
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL PRACTICE |
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial
,
Department of Anaesthesia and Intensive Care, St George's Hospital, London, UK Present addresses: 1 Department of Anaesthesia and Intensive Care, York Hospital, York, UK. 2 Intensive Care Unit, Liverpool Hospital, NSW, Australia. 3 Department of Anaesthesia, Mayo General Hospital, Co. Mayo, Ireland
* Corresponding author: Department of Anaesthesia and Intensive Care Medicine, St George's Hospital, Blackshaw Road, London SW17 0QT, UK. E-mail: michael.grounds{at}stgeorges.nhs.uk
Background. Activated recombinant coagulation factor VII (rFVIIa) effectively prevents and controls bleeding in patients with coagulopathy. Data show that rFVIIa may reduce blood loss and eliminate the need for transfusion in patients with normal haemostasis undergoing major surgery. We assessed the efficacy of rFVIIa in patients with normal haemostasis undergoing repair surgery of major traumatic fracture of the pelvis or the pelvis and acetabulum, who were expected to have a large volume of blood loss.
Methods. We performed a double-blind, randomized, placebo-controlled trial involving 48 patients undergoing major pelvic–acetabular surgery. Patients were randomized to receive an i.v. bolus injection of rFVIIa 90 µg kg–1 or placebo as add-on therapy at the time of the first skin incision. All patients also received intraoperative salvaged red blood cells (RBC).
Results. There was no significant difference in the total volume of perioperative blood loss, the primary outcome variable, between the rFVIIa and placebo groups. In addition, there were no differences between the two groups in the total volume of blood components, including salvaged RBC transfused, number of patients requiring allogeneic blood components, total volume of fluids infused, total operating time, time taken after entry to the intensive care unit to reach normal body temperature and acid–base status, and time spent in hospital. No adverse events, in particular thromboembolic events, were reported in either group.
Conclusions. In patients with normal haemostasis undergoing repair surgery of traumatic pelvic–acetabular fracture, the prophylactic use of rFVIIa does not decrease the volume of perioperative blood loss.
This article is accompanied by the Editorial.
Declaration of interest. R. M. Grounds has worked in the past as a consultant for Novo Nordisk and has lectured at symposiums organized by Novo Nordisk. Novo Nordisk has given an unrestricted educational grant to St George's Hospital Special Trustee's. The trial was funded by Novo Nordisk, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. E. Phillips, C. McLintock, W. Pollock, S. Gatt, P. Popham, G. Jankelowitz, R. Ogle, and P. A. Cameron Recombinant Activated Factor VII in Obstetric Hemorrhage: Experiences from the Australian and New Zealand Haemostasis Registry Anesth. Analg., December 1, 2009; 109(6): 1908 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kylasam, K. Mos, S. Fijtin, B. Webster, R. Chard, and J. Egan Recombinant Activated Factor VII Following Pediatric Cardiac Surgery J Intensive Care Med, March 1, 2009; 24(2): 116 - 121. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-F. Hardy, S. Belisle, and P. Van der Linden Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients: A Review of 17 Randomized Controlled Trials Ann. Thorac. Surg., September 1, 2008; 86(3): 1038 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ranucci, G. Isgro, G. Soro, D. Conti, and B. De Toffol Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials Arch Surg, March 1, 2008; 143(3): 296 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Grounds, C. Seebach, C. Knothe, P. Paluszkiewicz, T. S. Smith, E. Kasal, R. Lecumberri, R. Urbanec, T. Haas, M. Wujtewicz, et al. Use of Recombinant Activated Factor VII (Novoseven) in Trauma and Surgery: Analysis of Outcomes Reported to an International Registry J Intensive Care Med, January 1, 2006; 21(1): 27 - 39. [Abstract] [PDF]
|
|
|
|
|
|
W. H. Dzik Off-label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII J Intensive Care Med, January 1, 2006; 21(1): 54 - 59. [PDF]
|
|
|
|
 |
|
 P. Diprose, M. J. Herbertson, D. O'Shaughnessy, and R. S. Gill Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study Br. J. Anaesth., November 1, 2005; 95(5): 596 - 602. [Abstract] [Full Text] [PDF]
|
|